These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8175130)

  • 1. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.
    Tsubota A; Chayama K; Ikeda K; Yasuji A; Koida I; Saitoh S; Hashimoto M; Iwasaki S; Kobayashi M; Hiromitsu K
    Hepatology; 1994 May; 19(5):1088-94. PubMed ID: 8175130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.
    Hayashi J; Ohmiya M; Kishihara Y; Tani Y; Kinukawa N; Ikematsu H; Kashiwagi S
    Am J Gastroenterol; 1994 Dec; 89(12):2151-6. PubMed ID: 7977232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease.
    Sartori M; Andorno S; Avogadro E; Ballarè M; La Terra G; Leone F; Quaglia V; Fortina G; Aglietta M
    Ital J Gastroenterol; 1996; 28(8):452-6. PubMed ID: 9032588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological changes but not virus eradication reflect biochemical improvement in chronic hepatitis C patients showing a long-term response to interferon alpha therapy.
    Bruno S; Manzin A; Roncalli M; Petroni ML; Rossi S; Pedicino M; Larghi A; Crosignani A; Podda M
    Ital J Gastroenterol Hepatol; 1997 Feb; 29(1):31-7. PubMed ID: 9265576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
    Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
    Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.
    Enomoto M; Nishiguchi S; Shiomi S; Tanaka M; Yokogawa T; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Yano Y; Otani S
    Am J Gastroenterol; 2002 Feb; 97(2):420-6. PubMed ID: 11866282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes.
    Frangeul L; Cresta P; Perrin M; Lunel F; Opolon P; Agut H; Huraux JM
    Hepatology; 1998 Dec; 28(6):1674-9. PubMed ID: 9828234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon].
    Garrido A; Lepe JA; Guerrero FJ; Palomo S
    Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C.
    Chayama K; Tsubota A; Kobayashi M; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1996 May; 23(5):953-7. PubMed ID: 8621174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C.
    Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagata T; Tamaki J; Azuma M; Kishida Y; Yoshida A; Hikiji AY
    Hepatogastroenterology; 1995; 42(5):535-41. PubMed ID: 8751211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
    Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.